Company: CERO
Filing Date: 2025-08-22
Form Type: 10-Q
Source: 0001213900-25-079898
Chunk: 272

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-08-22
Form: 10-Q
Item: Item 2
Chunk 272
---
 (the “Plan”)
for regaining compliance with such requirements at a hearing conducted on December 17, 2025. The Company’s Plan included completion
of a reverse stock split, which occurred on January 8, 2025, and transferring the listing of its securities to the Nasdaq Capital Market,
which was completed on February 12, 2025, and certain other conditions, including the satisfaction of the $2.5 million minimum stockholders’
equity requirement for continued listing on the Nasdaq Capital Market.

In addition, as previously disclosed, from November 2024 through June
30, 2025, the Company raised approximately $3.1 million of net proceeds from its equity line of credit entered into November 2024, and
an additional approximately $4.3 million of net proceeds from its public offering of shares of common stock, pre-funded warrants and warrants
to purchase shares of common stock that closed on February 7, 2025 (the “February 2025 Offering”). As a result of such capital
raising activities and the proceeds of the Private Placement received on the First Closing Date, as well as successful negotiations with
certain service providers to reduce outstanding balances payable, the Company received a notification letter from Nasdaq on May 7, 2025,
stating that the Company had regained compliance with the Nasdaq continued listing standard under Nasdaq Listing Rule 5550(b)(1), which
requires, among other things, that the Company maintain at least $2.5 million in stockholders’ equity.

On
June 11, 2025, we received a Bid Price Requirement Letter notifying us that, for the 30 consecutive business day period between April
25, 2025 through June 9, 2025, the closing bid price for our Common Stock was below the minimum $1.00 per share required for continued
listing on The Nasdaq Capital Market set forth in Nasdaq Listing Rule 5550(a)(2), which is required for continued listing of the Common
Stock on Nasdaq. We timely appealed the delisting determination by requesting a hearing before the Nasdaq Panel. Such request for a Nasdaq
Panel hearing stayed the suspension of the Company’s securities. On July 7, 2025, Nasdaq informed us that they had determined that
we have regained compliance with the Bid Price Requirement and were therefore in compliance with the continued listing requirements.
As a result, Nasdaq canceled the hearing and the Common Stock will continue